ATE322280T1 - Verwendung von daptomycin - Google Patents
Verwendung von daptomycinInfo
- Publication number
- ATE322280T1 ATE322280T1 AT99949913T AT99949913T ATE322280T1 AT E322280 T1 ATE322280 T1 AT E322280T1 AT 99949913 T AT99949913 T AT 99949913T AT 99949913 T AT99949913 T AT 99949913T AT E322280 T1 ATE322280 T1 AT E322280T1
- Authority
- AT
- Austria
- Prior art keywords
- daptomycin
- administering
- muscle toxicity
- skeletal muscle
- effective amount
- Prior art date
Links
- 108010013198 Daptomycin Proteins 0.000 title abstract 6
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 title abstract 6
- 229960005484 daptomycin Drugs 0.000 title abstract 6
- 231100000483 muscle toxicity Toxicity 0.000 abstract 6
- 210000002027 skeletal muscle Anatomy 0.000 abstract 4
- 108010028921 Lipopeptides Proteins 0.000 abstract 2
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 abstract 2
- 229940052337 quinupristin/dalfopristin Drugs 0.000 abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10182898P | 1998-09-25 | 1998-09-25 | |
| US12575099P | 1999-03-24 | 1999-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE322280T1 true ATE322280T1 (de) | 2006-04-15 |
Family
ID=26798675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99949913T ATE322280T1 (de) | 1998-09-25 | 1999-09-24 | Verwendung von daptomycin |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6468967B1 (de) |
| EP (2) | EP1115417B1 (de) |
| JP (4) | JP4184607B2 (de) |
| KR (2) | KR20100051735A (de) |
| CN (2) | CN1150029C (de) |
| AT (1) | ATE322280T1 (de) |
| AU (1) | AU764348B2 (de) |
| BR (1) | BR9914051A (de) |
| CA (1) | CA2344318C (de) |
| CY (3) | CY1105556T1 (de) |
| DE (3) | DE122006000049I2 (de) |
| DK (2) | DK1674107T3 (de) |
| ES (2) | ES2259845T3 (de) |
| HK (1) | HK1040363B (de) |
| HU (1) | HU230656B1 (de) |
| IS (2) | IS5890A (de) |
| LU (1) | LU91254I2 (de) |
| NL (1) | NL300232I2 (de) |
| NO (1) | NO20011454L (de) |
| NZ (1) | NZ510690A (de) |
| PL (2) | PL203689B1 (de) |
| PT (2) | PT1674107T (de) |
| RU (1) | RU2363489C9 (de) |
| SI (2) | SI1674107T1 (de) |
| TR (1) | TR200100841T2 (de) |
| WO (1) | WO2000018419A2 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259845T3 (es) | 1998-09-25 | 2006-10-16 | Cubist Pharmaceuticals, Inc. | Uso de la daptomicina. |
| US6911525B2 (en) | 1999-12-15 | 2005-06-28 | Cubist Pharmaceuticals, Inc. | Lipopeptides as antibacterial agents |
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| NZ571597A (en) | 2000-12-18 | 2010-05-28 | Cubist Pharm Inc | Method for preparing crystalline and crystal-like forms of purified daptomycin lipopeptides |
| WO2002059145A1 (en) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
| US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| EP1932853A1 (de) | 2001-08-06 | 2008-06-18 | Cubist Pharmaceutical Inc. | Neue Depsipeptide und Herstellungsverfahren dafür |
| US20040147441A1 (en) * | 2002-08-23 | 2004-07-29 | Leach Timothy S. | Methods and reagents for preventing bacteremias |
| US20050277581A1 (en) * | 2002-11-18 | 2005-12-15 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20060074014A1 (en) * | 2002-11-18 | 2006-04-06 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20050220862A1 (en) | 2004-03-31 | 2005-10-06 | Bernstein Joel E | Compositions with reduced hepatotoxicity |
| US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
| US20080051326A1 (en) * | 2004-11-12 | 2008-02-28 | Alexander Dylan C | Antiinfective Lipopeptides |
| US8546423B2 (en) | 2005-05-18 | 2013-10-01 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US7838532B2 (en) * | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US20070238630A1 (en) * | 2006-03-29 | 2007-10-11 | Phillips Douglas H | Subcutaneous skin cleanser |
| EP2018864A1 (de) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmazeutische Zusammensetzung, Substrat mit einer pharmazeutischen Zusammensetzung und Verwendung einer pharmazeutischen Zusammensetzung |
| TW200940552A (en) * | 2008-03-04 | 2009-10-01 | Elan Pharm Inc | Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens |
| MX2011000696A (es) | 2008-07-17 | 2011-07-29 | Acorda Therapeutics Inc | Dosificacion terapeutica de una neurregulina o una subsecuencia de la misma para el tratamiento o la profilaxis de insuficiencia cardiaca. |
| DE102008046610A1 (de) * | 2008-09-09 | 2010-03-11 | Biomet Deutschland Gmbh | Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt |
| PT2346509T (pt) | 2008-10-07 | 2020-08-05 | Horizon Orphan Llc | Inalação de levofloxacina para redução da inflamação pulmonar |
| CN105520922A (zh) | 2008-10-07 | 2016-04-27 | 拉普特制药有限公司 | 用于改进的药物动力学的氟喹诺酮气雾剂制剂 |
| US8809263B2 (en) * | 2008-10-24 | 2014-08-19 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Anti-infective hydroxy-phenyl-benzoates and methods of use |
| NZ594019A (en) * | 2008-12-22 | 2013-08-30 | Cubist Pharm Inc | Novel antibacterial agents for the treatment of gram positive infections |
| TW201035111A (en) | 2008-12-23 | 2010-10-01 | Biosource Pharm Inc | Antibiotic compositions for the treatment of gram negative infections |
| US8450300B2 (en) * | 2009-07-13 | 2013-05-28 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| CA2767614C (en) * | 2009-07-13 | 2019-01-15 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| PT2473170T (pt) | 2009-09-04 | 2019-08-23 | Horizon Orphan Llc | Utilização de levofloxacina em aerossol para tratamento de fibrose cística |
| CA2781666C (en) | 2009-11-23 | 2017-02-21 | Cubist Pharmaceuticals, Inc. | Lipopeptide compositions and related methods |
| US8247394B2 (en) | 2010-06-02 | 2012-08-21 | Cempra Pharmaceuticals Inc. | Methods of treating urethritis and related infections using fusidic acid |
| US8415307B1 (en) | 2010-06-23 | 2013-04-09 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| WO2013059610A1 (en) | 2011-10-20 | 2013-04-25 | Trius Therapeutics, Inc. | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use |
| AU2013237939A1 (en) | 2012-03-30 | 2014-10-30 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
| NZ741342A (en) * | 2012-09-11 | 2019-10-25 | Hospira Australia Pty Ltd | Daptomycin formulations and uses thereof |
| CN103006562B (zh) * | 2013-01-21 | 2014-09-17 | 西南大学 | 达托霉素醇质体制剂 |
| KR102237887B1 (ko) | 2013-03-15 | 2021-04-07 | 멜린타 서브시디어리 코프. | 항생제를 사용하여 과체중 및 비만 환자에서 감염을 치료하는 방법 |
| US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
| US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
| CN109310735A (zh) * | 2016-05-13 | 2019-02-05 | 我希望增效剂公司 | 新阳离子肽spr741对抗生素活性的增效作用 |
| CN114788814B (zh) * | 2021-01-26 | 2023-10-13 | 浙江创新生物有限公司 | 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE32333E (en) | 1978-10-16 | 1987-01-20 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
| USRE32455E (en) | 1978-10-16 | 1987-07-07 | Eli Lilly And Company | A-21978 antibiotics and process for their production |
| US4537717A (en) | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| USRE32311E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4482487A (en) | 1982-05-21 | 1984-11-13 | Eli Lilly And Company | A-21978C cyclic peptides |
| US4524135A (en) | 1982-05-21 | 1985-06-18 | Eli Lilly And Company | A-21978C cyclic peptides |
| USRE32310E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4885243A (en) | 1984-10-09 | 1989-12-05 | Eli Lilly And Company | Process for producing A-21978C derivatives |
| US4800157A (en) | 1985-09-09 | 1989-01-24 | Eli Lilly And Company | Process for producing the A-21978C antibiotics |
| US4874843A (en) | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
| CA1315229C (en) | 1987-06-10 | 1993-03-30 | Patrick J. Baker | Chromatographic purification process |
| CA2011365A1 (en) * | 1989-03-06 | 1990-09-06 | Eugene L. Inman | Diluent formulation for daptomycin |
| FR2755857B1 (fr) | 1996-11-19 | 1998-12-24 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation |
| FR2772272B1 (fr) * | 1997-12-16 | 2000-01-14 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation |
| ES2259845T3 (es) | 1998-09-25 | 2006-10-16 | Cubist Pharmaceuticals, Inc. | Uso de la daptomicina. |
| US9393093B2 (en) | 2008-02-18 | 2016-07-19 | Covidien Lp | Clip for implant deployment device |
-
1999
- 1999-09-24 ES ES99949913T patent/ES2259845T3/es not_active Expired - Lifetime
- 1999-09-24 US US09/406,568 patent/US6468967B1/en not_active Expired - Lifetime
- 1999-09-24 PT PT60066974T patent/PT1674107T/pt unknown
- 1999-09-24 TR TR2001/00841T patent/TR200100841T2/xx unknown
- 1999-09-24 PL PL348328A patent/PL203689B1/pl unknown
- 1999-09-24 NZ NZ510690A patent/NZ510690A/xx not_active IP Right Cessation
- 1999-09-24 HU HU0103874A patent/HU230656B1/hu unknown
- 1999-09-24 KR KR1020107006807A patent/KR20100051735A/ko not_active Ceased
- 1999-09-24 BR BR9914051-9A patent/BR9914051A/pt not_active Application Discontinuation
- 1999-09-24 AT AT99949913T patent/ATE322280T1/de active
- 1999-09-24 DK DK06006697.4T patent/DK1674107T3/en active
- 1999-09-24 PL PL384274A patent/PL206091B1/pl unknown
- 1999-09-24 DK DK99949913T patent/DK1115417T3/da active
- 1999-09-24 CA CA002344318A patent/CA2344318C/en not_active Expired - Lifetime
- 1999-09-24 JP JP2000571937A patent/JP4184607B2/ja not_active Expired - Lifetime
- 1999-09-24 HK HK02100152.2A patent/HK1040363B/en not_active IP Right Cessation
- 1999-09-24 DE DE200612000049 patent/DE122006000049I2/de active Active
- 1999-09-24 CN CNB998124982A patent/CN1150029C/zh not_active Ceased
- 1999-09-24 AU AU62687/99A patent/AU764348B2/en not_active Expired
- 1999-09-24 CN CNA200410031708XA patent/CN1530136A/zh active Pending
- 1999-09-24 ES ES06006697.4T patent/ES2603086T3/es not_active Expired - Lifetime
- 1999-09-24 EP EP99949913A patent/EP1115417B1/de not_active Revoked
- 1999-09-24 WO PCT/US1999/022366 patent/WO2000018419A2/en not_active Ceased
- 1999-09-24 SI SI9931082A patent/SI1674107T1/sl unknown
- 1999-09-24 DE DE69930758T patent/DE69930758T2/de not_active Expired - Lifetime
- 1999-09-24 EP EP06006697.4A patent/EP1674107B8/de not_active Expired - Lifetime
- 1999-09-24 DE DE1999630758 patent/DE122006000049I1/de active Pending
- 1999-09-24 KR KR1020017003735A patent/KR20010075327A/ko not_active Ceased
- 1999-09-24 SI SI9930904T patent/SI1115417T1/sl unknown
- 1999-09-24 PT PT99949913T patent/PT1115417E/pt unknown
-
2001
- 2001-03-14 IS IS5890A patent/IS5890A/is unknown
- 2001-03-22 NO NO20011454A patent/NO20011454L/no not_active Application Discontinuation
-
2002
- 2002-02-20 US US10/082,544 patent/US6852689B2/en not_active Expired - Lifetime
-
2003
- 2003-05-27 JP JP2003149968A patent/JP2003321389A/ja not_active Withdrawn
-
2004
- 2004-03-04 RU RU2004106569/14A patent/RU2363489C9/ru active
- 2004-08-17 JP JP2004237765A patent/JP2004339238A/ja not_active Withdrawn
-
2006
- 2006-04-18 CY CY20061100536T patent/CY1105556T1/el unknown
- 2006-06-23 NL NL300232C patent/NL300232I2/nl unknown
- 2006-06-28 LU LU91254C patent/LU91254I2/fr unknown
- 2006-07-18 CY CY200600003C patent/CY2006003I1/el unknown
- 2006-09-22 JP JP2006258107A patent/JP2006335773A/ja not_active Withdrawn
-
2009
- 2009-03-10 IS IS8807A patent/IS8807A/is unknown
-
2016
- 2016-11-24 CY CY20161101219T patent/CY1118334T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE322280T1 (de) | Verwendung von daptomycin | |
| DK0713701T3 (da) | 2-Brommelatonin til behandling af søvnforstyrrelser | |
| ATE245977T1 (de) | Therapeutische substituierte guanidine | |
| ATE260658T1 (de) | Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen | |
| DK0583421T3 (da) | Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse | |
| DK1201246T3 (da) | Anvendelse af trombopoietin som et medikament til behandling og forebyggelse af trombocytopeni | |
| ES2160643T3 (es) | Composiciones que contienen g-csf y proteina de union al tnf. | |
| ES2106531T3 (es) | Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso. | |
| IL136733A0 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| GB2331926A (en) | Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine | |
| HUP0000110A2 (hu) | Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények | |
| DE69626050D1 (de) | Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren | |
| SE9803623D0 (sv) | New therapeutic application |